bit.bio has successfully defended its foundational European patent for opti-ox, a technology the company says enables deterministic forward programming of pluripotent stem cells (PSCs). Following an anonymous opposition filed on 5 January 2023 and a public hearing on 25 September 2024, the European Patent Office’s (EPO) Opposition Division has confirmed the patent's validity. The EPO […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!